All In Biotech

Drug Trial Radar · NCT07791745

A Clinical Trial Comparing the Efficacy and Safety of Anyouping® and Platinum-based Chemotherapy With or Without Enlituo® in Advanced Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.

A Prospective, Multicenter, Randomized, Controlled Phase II/III Study to Evaluate the Efficacy and Safety of Enlituo® Plus Anyouping® and Platinum-Based Chemotherapy Versus Anyouping® Plus Platinum-Based Chemotherapy as First-Line Treatment for Advanced, Recurrent or Metastatic of the Head and Neck Squamous Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 362 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

362

Planned (sponsor's estimate)

Start

Sep 16, 2026

Primary completion

Aug 30, 2032

Study completion Aug 30, 2032

Sponsor

Sponsor type
Industry
First posted
Aug 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Clinical Trial Comparing the Efficacy and Safety of Anyouping® and Platinum-based Chemotherapy With Enlituo® in Advanced Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.

Conditions

  • Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)

Interventions

  • Enlituo® + Anyouping® + PBCDrug

    Enlituo®:Enlituo® is administered according to the protocol. Anyouping®:Anyouping® is administered according to the protocol. Platinum-based chemotherapy (PBC):Cisplatin (DDP) or Carboplatin (CBP) plus Albumin-bound Paclitaxel (nab-paclitaxel) are administered according to the protocol.

  • Placebo-Enlituo + Anyouping® + PBCDrug

    Comparator in Phase 2 is Anyouping® + PBC. Comparator in Phase 3 is Placebo-Enlituo + Anyouping® + PBC. Placebo-Enlituo (only in Phase 3):Placebo-Enlituo is administered according to the protocol. Anyouping®:Anyouping® is administered according to the protocol. Platinum-based chemotherapy (PBC):Cisplatin (DDP) or Carboplatin (CBP) plus Albumin-bound Paclitaxel (nab-paclitaxel) are administered according to the protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (Phase 3)Time frame: Up to 2 years.
  2. Objective Response Rate (Phase 2)Time frame: Up to 2 years.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.